Targeting AMPK: a new therapeutic opportunity in breast cancer. Export

@article{citeulike:3343819, abstract = {BACKGROUND: This paper reviews the mammalian Target Of Rapamycin (mTOR) pathway dysregulation in breast cancer, and the current evidence targeting this pathway directly or through activation of AMP-activated protein kinase (AMPK) as an additional therapeutic opportunity for intervention in breast cancer. METHODS: Relevant articles were identified through computerised searches of Medline and Pubmed. Secondary articles were identified from the reference lists of key papers and by hand searching. RESULTS AND CONCLUSION: The current consensus to target the AMPK/mTOR pathway in breast cancer is based on in vitro and epidemiological evidences. A low incidence of cancer in diabetic patients on metformin has been explained in vitro by the drug's anti-proliferative effect through activation of AMPK. There is a need to explore the anticancer effects of metformin and the potential to develop the therapeutic avenues offered by targeting the AMPK/mTOR pathway.}, address = {Department of Surgery and Molecular Oncology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom. s.hadad@dundee.ac.uk}, author = {Hadad, S. M. and Fleming, S. and Thompson, A. M.}, citeulike-article-id = {3343819}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.critrevonc.2008.01.007}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/18343152}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=18343152}, doi = {10.1016/j.critrevonc.2008.01.007}, issn = {1040-8428}, journal = {Critical reviews in oncology/hematology}, keywords = {ampk, breast, cancer, mtor, therapeutic, therapy}, month = {July}, number = {1}, pages = {1--7}, posted-at = {2008-10-03 02:14:29}, priority = {2}, title = {Targeting AMPK: a new therapeutic opportunity in breast cancer.}, url = {http://dx.doi.org/10.1016/j.critrevonc.2008.01.007}, volume = {67}, year = {2008} }

TY - JOUR ID - citeulike:3343819 L3 - citeulike-article-id:3343819 N2 - BACKGROUND: This paper reviews the mammalian Target Of Rapamycin (mTOR) pathway dysregulation in breast cancer, and the current evidence targeting this pathway directly or through activation of AMP-activated protein kinase (AMPK) as an additional therapeutic opportunity for intervention in breast cancer. METHODS: Relevant articles were identified through computerised searches of Medline and Pubmed. Secondary articles were identified from the reference lists of key papers and by hand searching. RESULTS AND CONCLUSION: The current consensus to target the AMPK/mTOR pathway in breast cancer is based on in vitro and epidemiological evidences. A low incidence of cancer in diabetic patients on metformin has been explained in vitro by the drug's anti-proliferative effect through activation of AMPK. There is a need to explore the anticancer effects of metformin and the potential to develop the therapeutic avenues offered by targeting the AMPK/mTOR pathway. IS - 1 JF - Critical reviews in oncology/hematology SN - 1040-8428 AD - Department of Surgery and Molecular Oncology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom. s.hadad@dundee.ac.uk EP - 7 TI - Targeting AMPK: a new therapeutic opportunity in breast cancer. VL - 67 SP - 1 KW - ampk KW - breast KW - cancer KW - mtor KW - therapeutic KW - therapy AU - Hadad, SM AU - Fleming, S AU - Thompson, AM PY - 2008/07// UR - http://dx.doi.org/10.1016/j.critrevonc.2008.01.007 ER -